Halozyme and Janssen to develop and commercialise subcutaneous products Print
Friday, 19 December 2014 08:07
US-based Halozyme Therapeutics has signed a worldwide collaboration and licence agreement with Janssen Biotech to develop and commercialise subcutaneous products by using Enhanze technology.
read full article